Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Systolic
Interventions
ITI-214, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
Not listed
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Glendale, California • Imperial, California • Lemon Grove, California + 17 more
Conditions
Generalized Anxiety Disorder
Interventions
JNJ-99245354, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Temecula, California • Miami, Florida • Springfield, Massachusetts + 1 more
Conditions
Healthy Volunteers
Interventions
ITI-333, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Newport Beach, California + 14 more
Conditions
Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Conditions
Bipolar Depression, Major Depressive Disorder
Interventions
Lumateperone, Placebos
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Lumateperone high dose, Lumateperone low dose, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Little Rock, Arkansas • Sacramento, California • Sherman Oaks, California + 32 more
Conditions
Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • St Louis, Missouri
Conditions
Agitation Associated With Alzheimer's Dementia
Interventions
ITI-1284, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
55 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
32
States / cities
Anaheim, California • Costa Mesa, California • Garden Grove, California + 19 more
Conditions
Bipolar Depression
Interventions
ITI-007 (Lumateperone), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 52 more
Completed Phase 2 Interventional Results available

Caplyta in Borderline Personality Disorder

NCT05356013
Conditions
Borderline Personality Disorder
Interventions
Caplyta, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 2 Interventional Results available

ITI-007 (Lumateperone Tosylate) for Schizophrenia

NCT03817528
Conditions
Schizophrenia
Interventions
ITI-007
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy Volunteers
Interventions
ITI-333
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Creve Coeur, Missouri • St Louis, Missouri
Conditions
Alzheimer's Disease
Interventions
ITI-007, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
65 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Conditions
Psychotic Disorders, Alzheimer Disease
Interventions
ITI-1284, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
55 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Newport Beach, California + 20 more
Conditions
Schizophrenia or Schizoaffective
Interventions
Lumateperone Capsule, Lumateperone LAI
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey
Conditions
Schizophrenia, Pediatric
Interventions
Lumateperone 42 mg, Lumateperone 28 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
Conditions
Schizophrenia
Interventions
Lumateperone Long-Acting Injectable
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Conditions
Schizophrenia
Interventions
ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • New York, New York
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 21 more
Conditions
Bipolar Depression
Interventions
Lumateperone (ITI-007), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
42
States / cities
Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement

NCT03489772
Conditions
Healthy Volunteers
Interventions
ITI-214, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Parkinson Disease
Interventions
Lenrispodun, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more